Samsung Peptide Launches Tender Offer for PolyPeptide Group

Samsung Peptide AG, a subsidiary of Samsung Biologics, has published an offer prospectus for the public tender offer for all registered shares of PolyPeptide Group AG. The bid values PolyPeptide's equity at CHF 1.46 billion, offering CHF 44.31 per share. This represents a 40% premium over the last unaffected closing price of April 2026.

PolyPeptide's Board unanimously recommends shareholder acceptance, supported by a fairness opinion from IFBC AG. Draupnir Holding B.V., the largest shareholder, will tender its 55.65% stake. The offer period runs from 15 September to 12 October 2026, subject to customary conditions.

The deal, subject to regulatory approvals, includes plans for a squeeze-out procedure and delisting from the SIX Swiss Exchange post-settlement. Further details and documentation can be accessed online.